Ja. Sosman et al., Interleukin 10-induced thrombocytopenia in normal healthy adult volunteers: evidence for decreased platelet production, BR J HAEM, 111(1), 2000, pp. 104-111
Recombinant human interleukin 10 (rhuIL-10) inhibits the production of proi
nflammatory cytokines and has shown promise in the treatment of inflammator
y bowel disease. Clinical trials have been accompanied by a reversible decl
ine in platelet counts. We conducted a randomized, double-blinded, placebo-
controlled, parallel group trial in 12 healthy Volunteers to investigate th
e aetiology of rhuIL-10-induced thrombocytopenia. Eight volunteers received
8 mug/kg/d of rhuIL-10 subcutaneously, while four subjects received a plac
ebo alone for 10 d. A reversible decline in the platelet counts from a mean
of 275 x 10(9)/l to 164 x 10(9)/l was observed in the IL-10-treated cohort
(P = 0.012). A fall in the haemoglobin mean levels was also observed in th
e IL-10-treated cohort from 13.7 to 11.7 g/dl (P = 0.011). No significant c
hange was observed in the bone marrow cellularity or myeloid/ erythroid rat
io or in the number of megakaryocytes per high-powered field (HPF). A fall
was observed in the number of megakaryocyte colony-forming units (CFU-MKs)
after the administration of IL-10 compared with those receiving the placebo
(P = 0.068). No difference in the change in granulocyte-macrophage CFUs (C
FU-GMs), mixed lineage CFUs (CFU-GEMMs) or erythroid burst-forming units (B
FU-Es) was observed when comparing the IL-10- vs. placebo-treated groups (P
> 0.465). Serum cytokine levels of thrombopoietin (TPO), IL-6 and granuloc
yte-macrophage colony stimulating factor (GM-CSF) were not decreased follow
ing IL-10 administration, In fact, both TPO and GMCSF appeared to be slight
ly increased in the serum. All subjects underwent In-111-labelled platelet
survival studies with liver/spleen scans to assess splenic sequestration pr
ior to and then on day 7 of treatment. A significant reduction in splenic s
equestration of platelets (P = 0.012) was observed in the IL-10-treated gro
up, but not in the placebo-treated subjects.